Teva Pharmaceutical Industries Ltd. (TEVA) sued Synthon BV for infringing seven patents in planning to sell a generic version of the multiple sclerosis drug Copaxone before Teva’s patents expire.
Teva, based in Petach Tikva, Israel, said it licensed the patents from Yeda Research & Development Co., according to the lawsuit filed yesterday in federal court in New York.
Copaxone, used to reduce the frequency of relapses in multiple sclerosis patients, generated sales (TEVA) of $3.9 billion in 2011. Synthon filed an application with the U.S. Food and Drug Administration seeking approval of a generic version of the drug, according to the complaint.
“Defendants plan to begin manufacturing, marketing, selling, offering to sell and/or importing Synthon’s generic glatiramer acetate product soon after FDA approval,” Teva said in the complaint. “Such conduct will constitute direct infringement.”... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1903
